ReviewPhysiological genomics2018
Genetic and microbiome influence on lipid metabolism and dyslipidemia.
Review in Physiological genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 133 citations in OpenAlex.
- Gut microbiome responses to dietary intervention with hypocholesterolemic vegetable oils.NPJ biofilms and microbiomes · 2022Trial
- Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities.Scientific reports · 2019Trial
- The association between T4 and TSH with lipid profile is attenuated in patients with established dyslipidemia.BMC endocrine disorders · 2026Article
- Gut microbial community structure, metabolic signature, and resistome in dyslipidemia: implications for cardiovascular disease management.Microbiology spectrum · 2026Article
- Gut microbiota orchestrates bone homeostasis: a multi-pathway network from intestine to skeleton.Frontiers in endocrinology · 2026Review
- Photoperiod effects on growth, lipid metabolism, and lipidomics analysis of tilapia.Frontiers in physiology · 2026Article
- Oral microbial alterations by smoking and metabolic factors in esophageal squamous cell carcinoma.Journal of gastrointestinal oncology · 2025Article
- The Role of the Microbiome and the Neurovascular Unit.The Surgical clinics of North America · 2025Review
- Mechanisms Linking Obesity with Non-Alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Diseases (CVDs)-The Role of Oxidative Stress.Current issues in molecular biology · 2025Review
- Lactase Persistence-Associated rs4988235 Polymorphism: A Novel Genetic Link to Cardiovascular Risk via Modulation of ApoB100 and ApoAI.Nutrients · 2025Article
- Risk of remnant cholesterol and chronic obstructive pulmonary disease: a mendelian randomization study.Journal of thoracic disease · 2025Article
- Multi-trajectories of BMI, waist circumference, gut microbiota, and incident dyslipidemia: a 27-year prospective study.mSystems · 2025Article
- Article
- Altered gut microbiome and serum metabolome profiles associated with essential tremor.Metabolic brain disease · 2025Article
- Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis.Journal of lipid and atherosclerosis · 2025Article
- Association between the ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) and chronic kidney disease risk: a large-scale cross-sectional study in a Chinese population.Frontiers in medicine · 2025Article
- Primary Prevention Strategy for Non-Communicable Diseases (NCDs) and Their Risk Factors: The Role of Intestinal Microbiota.Biomedicines · 2024Review
- Interplays of Dietary Fat with BMI andFood science & nutrition · 2024Article
- NPC1L1 rs217434 A > G as a Novel Single Nucleotide Polymorphism Related to Dyslipidemia in a Korean Population.Biochemical genetics · 2024Article
- Helicobacter pylori infection increases the risk of dyslipidemia in Chinese diabetic Population: a retrospective cross-sectional study.BMC infectious diseases · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Disruption in the metabolism of lipids is broadly classified under dyslipidemia and relates to the concentration of lipids in the blood. Dyslipidemia is a predictor of cardio-metabolic disease including obesity. Traditionally, the large interindividual variation has been related to genetic factors and diet. Genome-wide association studies have identified over 150 loci related to abnormal lipid levels, explaining ~40% of the total variation. Part of the unexplained variance has been attributed to environmental factors including diet, but the extent of the dietary contribution remains unquantified. Furthermore, other factors are likely to influence lipid metabolism including the gut microbiome, which plays an important role in the digestion of different dietary components including fats and polysaccharides. Here we describe the contributing role of host genetics and the gut microbiome to dyslipidemia and discuss the potential therapeutic implications of advances in understanding the gut microbiome to the treatment of dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.